All In MedTech

FDA Clearance Tracker · K252360

ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Mar 28, 2026 (this decision)Source: openFDAMethods & limitations

510(k)Breakthrough

Decided

Mar 28, 2026

Substantially Equivalent

Time to decision

242 days

Received Jul 29, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K252360
Device name
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)
Applicant
Anumana, Inc.
Applicant location
Cambridge, MA
Received
Jul 29, 2025
Decided
Mar 28, 2026
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 870.2380

Every decision under product code SAT

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code SAT. The earliest in FDA's data is K233666, decided Apr 5, 2024.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Anumana, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.